Guanxin Danshen Dripping Pills Improve Quality of Life and Cardiovascular Prognoses of CHD Patients after PCI with Anxiety or Depression (GLAD Study): A Randomized Double-Blind Placebo-Controlled Study

Objective To assess the efficacy and safety of Guanxin Danshen Dripping Pills (GXDS) in the treatment of depression or anxiety in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI). Methods From September 2017 to June 2019, 200 CHD patients after PCI with depre...

Full description

Saved in:
Bibliographic Details
Published in:Chinese journal of integrative medicine 2023-03, Vol.29 (3), p.195-204
Main Authors: Wang, Cheng-long, Huan, Na, Wang, Pei-li, Geng, Qing-shan, Ma, Wen-lin, Ma, Li-hong, Jiang, Hong-yan, Meng, Xiao-ping, Zhang, Da-wu, Gou, Xiao-jiang, Hu, Da-yi, Chen, Ke-ji
Format: Article
Language:English
Subjects:
Angina Pectoris - drug therapy
Anxiety
Coronary Disease - drug therapy
Depression
Double-Blind Method
Drugs, Chinese Herbal - therapeutic use
Humans
Medicine
Medicine & Public Health
Original Article
Percutaneous Coronary Intervention - adverse effects
Prognosis
Quality of Life
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To assess the efficacy and safety of Guanxin Danshen Dripping Pills (GXDS) in the treatment of depression or anxiety in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI). Methods From September 2017 to June 2019, 200 CHD patients after PCI with depression and anxiety were included and randomly divided into GXDS (100 cases) and placebo control groups (100 cases) by block randomization and a random number table. Patients in the GXDS and control groups were given GXDS and placebo, respectively, 0.4 g each time, 3 times daily for 12 weeks. The primary outcomes were scores of Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Scale (GAD-7) and the Seattle Angina Pectoris Scale (SAQ). The secondary outcomes included 12 Health Survey Summary Form (SF-12) scores and the first onset time and incidence of major adverse cardiovascular events (MACEs). Other indices including blood pressure, blood lipids, microcirculation and inflammatory-related indices, etc. were monitored at baseline, week 4, and week 12. Results In the full analysis set (200 cases), after treatment, the PHQ-9 and GAD-7 scores in the GXDS group were considerably lower than those in the control group ( P
ISSN:1672-0415
1993-0402
DOI:10.1007/s11655-022-3688-3